There is still considerable uncertainty about the accurate classification of human hematopoietic tumors, as well as great variability in prognosis and in response to treatment, not only among different tumors, but also within any one diagnostic category. More precise diagnosis and definition of the relationships between these tumors is therefore important, not only in terms of reaching a clearer understanding of their cellular orgins, but also in predicting prognosis, evaluating current treatment regimens, and developing more effective methods of therapy. The main purpose of this renewal application for this Program Projectr remains the same, namely to carry out a comprehensive clinical-laboratory investigation of all varieties of hematopoietic tumors, with emphasis on correlating the results of newer laboratory studies which have potential clinical relevance with conventional hematological and pathological diagnostic criteria, and with clinical data on staging, responsiveness to treatment, and survival. The investigations include determination of surface and biochemical markers and specific receptors, cytokinetic parameters of tumor cells and subpopulations, size distribution, clonogenic potential in short-term culture systems, response to mitogens, physiologic regulators and drugs, interactions with other cell types in culture, establishment of human tumor cell lines, correlation of specific cytogenetic abnormalities with cell type and prognosis, cytofluorometric measurements of DNA and RNA content and cell cycle distribution and preparation of monoclonal antibodies to specific cell types. The eventual goals are to develop an objective and scientific classification system for human hematopoietic tumors based on the origins and functional properties of the cells, to identify the critical prognostic factors at the time of diagnosis, and to develop more selective and effective treatment programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA020194-11
Application #
3092876
Study Section
Clinical Cancer Program Project Review Committee (CCP)
Project Start
1984-01-01
Project End
1991-12-31
Budget Start
1988-01-01
Budget End
1988-12-31
Support Year
11
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Gabrilove, J L; White, K; Rahman, Z et al. (1994) Stem cell factor and basic fibroblast growth factor are synergistic in augmenting committed myeloid progenitor cell growth. Blood 83:907-10
Wisniewski, D; Strife, A; Wojciechowicz, D et al. (1994) A 62-kilodalton tyrosine phosphoprotein constitutively present in primary chronic phase chronic myelogenous leukemia enriched lineage negative blast populations. Leukemia 8:688-93
Brunner, G; Metz, C N; Nguyen, H et al. (1994) An endogenous glycosylphosphatidylinositol-specific phospholipase D releases basic fibroblast growth factor-heparan sulfate proteoglycan complexes from human bone marrow cultures. Blood 83:2115-25
Crown, J; Jakubowski, A; Gabrilove, J (1993) Interleukin-1: biological effects in human hematopoiesis. Leuk Lymphoma 9:433-40
Gabrilove, J L; Wong, G; Bollenbacher, E et al. (1993) Basic fibroblast growth factor counteracts the suppressive effect of transforming growth factor-beta 1 on human myeloid progenitor cells. Blood 81:909-15
Offit, K; Parsa, N Z; Jhanwar, S C et al. (1993) Clusters of chromosome 9 aberrations are associated with clinico-pathologic subsets of non-Hodgkin's lymphoma. Genes Chromosomes Cancer 7:1-7
Shieh, J H; Peterson, R H; Moore, M A (1993) Cytokines and dexamethasone modulation of IL-1 receptors on human neutrophils in vitro. J Immunol 150:3515-24
Offit, K; Parsa, N Z; Gaidano, G et al. (1993) 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood 82:2157-62
Rao, P H; Murty, V V; Gaidano, G et al. (1993) Subregional localization of 20 single-copy loci to chromosome 6 by fluorescence in situ hybridization. Genomics 16:426-30
Muench, M O; Firpo, M T; Moore, M A (1993) Bone marrow transplantation with interleukin-1 plus kit-ligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem cell lineage and proliferative potential. Blood 81:3463-73

Showing the most recent 10 out of 152 publications